Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;7(5):1285-1290.
doi: 10.3892/etm.2014.1597. Epub 2014 Mar 4.

Effect of metformin on the human T98G glioblastoma multiforme cell line

Affiliations

Effect of metformin on the human T98G glioblastoma multiforme cell line

Alı Ucbek et al. Exp Ther Med. 2014 May.

Abstract

Metformin is a guanidine derivative found in Galega officinalis that is commonly used to treat diabetes mellitus. The mechanism of action of metformin involves regulation of the adenosine monophosphate-activated protein kinase/mammalian target of rapamycin signaling pathway, which is implicated in the control of protein synthesis and cell proliferation. This led to the hypothesis that metformin reduces the risk of cancer and slows tumor growth. Thus, in the present study, the effectiveness of metformin as an antiglioma agent was evaluated using the human T98G glioblastoma multiforme cell line. The viability of the T98G cells was assessed using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Apoptosis was monitored by measuring caspase-3 levels, as well as by terminal deoxynucleotidyl transferase dUTP nick end labeling and staining with acridine orange and ethidium bromide. The results demonstrate that metformin reduced cell viability and caused apoptotic morphological changes in the T98G cells. Furthermore, the caspase-3 levels in the metformin-treated T98G cells were higher than those in the control cells. Metformin induced apoptosis in the T98G cell line in a concentration-dependent manner. Metformin may provide an important contribution to the treatment of glioblastoma multiforme.

Keywords: T98G; apoptosis; glioblastoma cell line; metformin.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MTT assay viability results in T98G cells. Viability of the T98G cells in the 24 h presence of (A) metformin (1, 5, 10, 50 and 100 mM) and (B) metformin (1, 5, 10, 50 and 100 mM) + 2.5 mM H2O2 combination. All data are expressed as the mean and SE from three independent experiments. *P<0.001 vs. control, #P<0.001 vs. 2.5 mM H2O2. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.
Figure 2
Figure 2
Fold increase in caspase 3 activity in T98G cells. (A) Metformin (1, 5, 10, 50 and 100 mM) and (B) metformin (1, 5, 10, 50 and 100 mM) + 2.5 mM H2O2 combination. All data are expressed as the mean and SE from three independent experiments. *P<0.001 vs. control, #P<0.001 vs. 2.5 mM H2O2.
Figure 3
Figure 3
Ethidium bromide and acridine orange fluorescein dye in the T98G cell line (magnification ×400). Apoptotic cells are indicated with an arrowhead. (A) Control, (B) 2.5 mM H2O2, (C) 1 mM metformin, (D) 1 mM metformin + 2.5 mM H2O2, (E) 5 mM metformin, (F) 5 mM metformin + 2.5 mM H2O2, (G) 10 mM metformin, (H) 10 mM metformin + 2.5 mM H2O2, (I) 50 mM metformin, (J) 50 mM metformin + 2.5 mM H2O2, (K) 100 mM metformin, (L) 100 mM metformin + 2.5 mM H2O2.
Figure 4
Figure 4
Apoptosis by TUNEL assay of the T98G cell line (magnification ×400). Apoptotic cells are indicated with an arrowhead. (A) Control, (B) 2.5 mM H2O2, (C) 1 mM metformin, (D) 1 mM metformin + 2.5 mM H2O2, (E) 5 mM metformin, (F) 5 mM metformin + 2.5 mM H2O2, (G) 10 mM metformin, (H) 10 mM metformin + 2.5 mM H2O2, (I) 50 mM metformin, (J) 50 mM metformin + 2.5 mM H2O2, (K) 100 mM metformin, (L) 100 mM metformin + 2.5 mM H2O2. TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling.

Similar articles

Cited by

References

    1. Campbell IW. Metformin - life begins at 50: A symposium held on the occasion of the 43rd Annual Meeting of the European Association for the Study of Diabetes, Amsterdam, The Netherlands, September 2007. (Meeting Report) Br J Diabet Vasc Dis. 2007;7:247–252.
    1. Li J, Deng J, Sheng W, Zuo Z. Metformin attenuates Alzheimer’s disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav. 2012;101:564–574. - PMC - PubMed
    1. Wahlqvist ML, Lee MS, Hsu CC, Chuang SY, Lee JT, Tsai HN. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson’s disease occurring with Type 2 diabetes in a Taiwanese population cohort. Parkinsonism Relat Disord. 2012;18:753–758. - PubMed
    1. Gallagher EJ, LeRoith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. Ann NY Acad Sci. 2011;1243:54–68. - PubMed
    1. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32:1620–1625. - PMC - PubMed

LinkOut - more resources